1. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects.
- Author
-
Karatrasoglou, Eleni A., Dimou, Maria, Piperidou, Alexia, Lakiotaki, Eleftheria, Korkolopoulou, Penelope, and Vassilakopoulos, Theodoros P.
- Subjects
- *
B cell lymphoma , *B cells , *MANTLE cell lymphoma , *PHOSPHATIDYLINOSITOL 3-kinases , *DIFFUSE large B-cell lymphomas , *ONCOGENES , *MTOR inhibitors - Abstract
Non-Hodgkin lymphoma's (NHL) incidence is rising over time, and B cell lymphomas comprise the majority of lymphomas. The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homologue 1 (Akt)/mammalian target of the rapamycin (mTOR) signaling pathway plays a critical role in a variety of cellular processes, such as cell proliferation and survival. Its role in lymphomagenesis is confirmed in many different types of B cell lymphomas. This review is mainly focused on the PI3K/v-akt/mTOR pathway-related oncogenic mechanisms in B cell NHLs with an emphasis on common B cell lymphoma types [diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)]. Furthermore, it summarizes the literature regarding the clinical applications of the mTOR inhibitors temsirolimus and everolimus in B cell NHLs, which have been tested in a range of clinical trials enrolling patients with B cell malignancies, either as monotherapy or in combination with other agents or regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF